MedTrace Logo

A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia

NCT02880462 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2020-03-24

No results posted yet for this study

Summary

The goal of the study is to investigate whether adding different doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.

This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

Conditions

Interventions

DIETARY_SUPPLEMENT

sulforaphane

Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.

OTHER

placebo

Placebo is made of starch

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Central South University

    lead OTHER

Principal Investigators

  • Jianjun Ou, M.D Ph.D · Central South University

  • Renrong Wu, M.D Ph.D · Central South University

  • Jingping Zhao, M.D Ph.D · Central South University

  • Hua Jin, M.D Ph.D · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-26
Primary Completion
2019-05-20
Completion
2019-05-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880462 on ClinicalTrials.gov